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Abstract
Background: There are limited data of immunologic and virologic failure in Asian HIV-infected children using non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based highly active antiretroviral therapy (HAART). We examined
the incidence rate of immunologic failure (IF) and virologic failure (VF) and the accuracy of using IF to predict VF in
Thai HIV-infected children using first-line NNRTI-based HAART.
Methods: Antiretroviral (ART)-naïve HIV-infected children from 2 prospective cohorts treated with NNRTI-based
HAART during 2001-2008 were included. CD4 counts were performed every 12 weeks and plasma HIV-RNA
measured every 24 weeks. Immune recovery was defined as CD4%≥25%. IF was defined as persistent decline of
≥5% in CD4% in children with CD4%<15% at baseline or decrease in CD4 count ≥30% from baseline. VF was
defined as HIV-RNA>1,000 copies/ml after at least 24 weeks of HAART. Clinical and laboratory parameter changes
were assessed using a paired t-test, and a time to event approach was used to assess predictors of VF. Sensitivity
and specificity of IF were calculated against VF.
Results: 107 ART-naive HIV-infected children were included, 52% female, % CDC clinical classification N:A:B:C
4:44:30:22%. Baseline data were median (IQR) age 6.2 (4.2-8.9) years, CD4% 7 (3-15), HIV-RNA 5.0 (4.9-5.5)
log10copies/ml. Nevirapine (NVP) and efavirenz (EFV)-based HAART were started in 70% and 30%, respectively.
At 96 weeks, none had progressed to a CDC clinical classification of AIDS and one had died from pneumonia.
Overall, significant improvement of weight for age z-score (p = 0.014), height for age z-score, hemoglobin, and
CD4 were seen (all p < 0.001). The median (IQR) CD4% at 96 weeks was 25 (18-30)%. Eighty-nine percent of
children had immune recovery (CD4%≥25%) and 75% of children had HIV-RNA <1.7log10copies/ml.
Thirty five (32.7%) children experienced VF within 96 weeks. Of these, 24 (68.6%) and 31 (88.6%) children had VF in
the first 24 and 48 weeks respectively.
Only 1 (0.9%) child experienced IF within 96 weeks and the sensitivity (95%CI) of IF to VF was 4 (0.1-20.4)% and
specificity was 100 (93.9-100)%.
Conclusion: Immunologic failure, as defined here, had low sensitivity compared to VF and should not be
recommended to detect treatment failure. Plasma HIV-RNA should be performed twice, at weeks 24 and 48, to
detect early treatment failure.
Trial Registration: Clinicaltrials.gov identification number NCT00476606
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Background
Over 140,000 children in South and Southeast Asia are
living with HIV [1]. Treatment with highly active antire-
troviral therapy (HAART) has increased the life expec-
tancy of HIV-infected children [2-6]. Non-nucleoside
reverse transcriptase inhibitor (NNRTI)-based HAART is
commonly prescribed as the first-line regimen in
resource-limited settings [2-8]. In Thailand, the majority
of HIV-infected individuals have HIV-1 subtype
CRF01_AE [9]. A national program has provided free
HAART since 2004 [2,3].
HIV care and monitoring in resource-limited settings
rely on clinical and immunologic monitoring. Virologic
monitoring is not commonly used due to the high cost
and limited access. Current WHO HIV treatment guide-
lines in resource-limited settings do not recommend rou-
tine plasma HIV-RNA measurement, rather they suggest
using immunologic criteria for making decisions about
treatment failure [10]. Mee et al. reported low sensitivity
of CD4 criteria of 21.2% in detecting virologic failure in
African HIV-infected adults [11]. Immunologic failure
criteria have poor accuracy and are estimated to lead to
premature switching to second-line regimens for 43-58%
of HIV-infected adults who experience a decrease in CD4
cell count [12]. Reports in African HIV-infected children
have shown low sensitivity of 3.5% of clinical and immu-
nologic criteria based on the WHO criteria for IF avail-
able at that time [2007] in identifying virologic failure
[13].
There are limited data on the sensitivity and specificity
of immunologic compared to virologic failure in Asian
HIV-infected children. Therefore, we aimed to report the
incidence rate of virologic failure and immunologic failure
and the accuracy of using immunologic failure to predict
virologic failure within 96 weeks of initiating first-line
NNRTI-based HAART in HIV-infected children.
Materials and methods
Data from HIV-infected children who were enrolled in 2
prospective cohorts at the HIV Netherlands Australia
Thailand Research Collaboration (HIV-NAT), the Thai
Red Cross AIDS Research Centre, Bangkok and Khon
Kaen University, Khon Kaen, Thailand from December
2001 to March 2008 were used. The inclusion criteria for
this study were HIV-infected children aged 1-18 years at
enrolment who were antiretroviral therapy (ART) naïve
before initiating first-line NNRTI-based HAART. The
criteria to start HAART in these HIV-infected children
followed WHO 2006 guidelines [14] and Thai 2008
guidelines [15]; CDC clinical classification C, or CD4%
<20% in children aged < 3 years, or CD4%<15% in chil-
dren aged ≥ 3 years [14,15]. The ART regimen and
dosages were calculated according to a child’s body
weight or body surface area according to recommenda-
tions in the WHO 2006 guidelines [14] and Thai 2008
guidelines [15]. Adherence counselling was performed at
each visit according to standard practice. The self-report
adherence questionnaires were completed by caregivers
at every visit. The missing doses in the last 3 days or
missing > 15 doses since last visit were defined as poor
adherence.
The children were assessed every 12 weeks for CDC
clinical classification, weight and height measurements,
complete blood count, CD4 percent and CD4 cell count
and alanine transferase (ALT). Plasma HIV- RNA, Roche
Amplicor Ultrasensitive assay, Palo Alto and USA were
performed every 24 weeks from 2007. The plasma, which
had been stored every 24 weeks during 2001-2006, was
tested retrospectively for HIV-RNA and included in this
analysis. Fasting lipid profiles and glucose were per-
formed every 24 weeks since June 2006. Clinical and
laboratory adverse events (AEs) were graded according to
the Division of AIDS toxicity table 2004 [16]. The ethics
committees at the institutions in both Bangkok and
Khon Kaen approved the study, and all caregivers signed
written informed consent.
Definitions
Immune recovery was defined as recovery of CD4 to ≥
25% after HAART initiation [17]. Immunologic failure
(IF) was defined as persistent decline of ≥ 5% in CD4%
in children with CD4% <15% at baseline or decrease
CD4 count ≥ 30% from baseline [18]. Virologic suppres-
sion was defined as HIV-RNA <1.7 log10copies/ml. Viro-
logic failure (VF) was defined as plasma HIV-RNA more
than 1,000 copies/ml after 24 weeks of HAART initia-
tion [5,19]. Elevated total cholesterol (TC), triglyceride
(TG) and reduced high density lipoprotein (HDL) were
defined as TC ≥ 200 mg/dl, TG ≥ 150 mg/dl and HDL
< 40 mg/dl [20].
Statistical analysis
Statistical analysis was performed with SAS version 9.1
(SAS Institute Inc, Cary, NC, USA) and with Stata ver-
sion 11 (Statacorp, College Station, TX, USA). Changes
in weight, height, and laboratory parameters from base-
line to weeks 48 and 96 were calculated and a formal
comparison using a paired t-test was made at week 96.
Patients changing from NNRTI-based regimens to PI-
based regimens for reasons other than virologic failure
were censored at this point and no extrapolation of data
was used. The Kaplan-Meier method was used to assess
the proportion of patients with virologic failure and Cox
Proportional Hazards regression was used to assess the
relative risk of failure. Significance was assessed using a
2-sided p-value of 0.05.
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Results
One hundred and seven HIV-infected children were
included in the analysis. The median (IQR) age was 6.2
(4.2-8.9) years, 52.3% were female. Zidovudine (AZT), and
stavudine (d4T) were used in 60.4% and 39.6%, respec-
tively. All used lamivudine (3TC). Nevirapine (NVP) and
efavirenz (EFV)-based HAART were prescribed 70% and
30%, respectively. The median (IQR) baseline CD4% and
HIV-RNA were 7 (3-15) and 5.0 (4.9-5.5) log10 copies/ml
(Table 1).
During 96 weeks of follow-up, there were 2 deaths: one
girl died in a car accident after 48 weeks and one boy died
at week 12 due to pneumonia. No children had disease
progression of CDC clinical classification. Improvement of
median z-score of weight for age (p = 0.014) and height
for age (p < 0.001) compared to baseline visit are shown
(Table 2). For laboratory results, improvement of hemo-
globin, CD4% and CD4 count were found (all p < 0.001).
At 96 weeks, 89% of children had immune recovery and
75% had HIV-RNA < 1.7 log10 copies/ml (Table 2).
One child experienced IF and VF at week 24 and his
CD4 was improved after switch to second-line therapy.
Thirty-five children experienced VF within 96 weeks. Of
these, 24 (68.6%) and 31 (88.6%) children had VF in the
first 24 and 48 weeks respectively. A Kaplan-Meier graph
of VF is presented in Figure 1.
During the study period, 17 (22.1%) of 77 children who
had completed data of adherence questionnaires were
noted to have poor adherence by history. Three of these
17 children had VF. There was no association between
poor adherence by history and VF (p = 0.24).
Predictors of virologic failure
In univariate Cox’s regression to identify the predictor
of VF, the hazard ratio (95% confidence interval) for
gender, male versus female was 0.92 (0.47-1.80), age at
NNRTI-based HAART initiation, > 6 years versus ≤ 6
years was 0.70 (0.36-1.37), CD4% at NNRTI-based
HAART initiation, ≤ 7:versus > 7% was 1.08 (0.55-2.12),
CDC clinical classification, C versus non C was 1.03
(0.47-2.27), NNRTI type, NVP versus EFV was 1.46
(0.66-3.22), HIV-RNA log10 at NNRTI-based HAART
initiation, > 5 versus ≤ 5 was 1.35 (0.65-2.81). Since no
factors were significant in univariate analysis, no multi-
variate model was developed.
Sensitivity and specificity of immunologic failure
One child experienced IF at week 24. The sensitivity and
specificity (95% confidence interval; CI) of IF to VF were
4 (0.1-20.4)% and 100 (93.9-100)%, respectively. Positive
predictive value and negative predictive value were 100
(2.5-100)% and 71.1 (60.1-80.5)%, respectively.
Severe adverse events
One girl aged 13 years had intermittent elevated ALT
grade 3-4 from week 4 related to chronic hepatitis B infec-
tion. One boy aged 5 years with baseline hemoglobin
11.4 g/dL, initiated treatment with zidovudine/lamivudine/
nevirapine and developed grade 4 anemia (hemoglobin
5.4 g/dL) at week 36. After receiving packed red cell trans-
fusion he was switched to stavudine/lamivudine/nevira-
pine, the clinical condition was improved at week 48 with
hemoglobin 12.1 g/dL.
At 96 weeks, 64 (60%) children had fasting TG and TC
results and 40 (37%) children had fasting HDL results
available. The median (IQR) TC was 187(157 - 212), TG
was 84(68-110.5), and HDL was 62(46 - 79) mg/dL. The
proportion of children with elevated TC was 32.8%, ele-
vated TG was 7.8%, and reduced HDL was 6.3%.
Discussion
At 96 weeks after NNRTI-based HAART initiation, HIV-
infected children had significant improvement of growth,
hemoglobin, CD4%, and CD4 count. Only 1 child experi-
enced IF. VF mostly occurred within the first 24 weeks of
NNRTI-based HAART but a quarter developed failure
between 24 to 48 weeks. To detect early treatment failure,
having two HIV-RNA monitorings within the first year, at
weeks 24 and 48, would be ideal. Low sensitivity of IF to
predict VF was found.
Growth was significantly improved after commencement
of NNRTI-based HAART in HIV-infected children [3]. In
our report, we found the same significant improvement of
weight for age and height for age z-score as found in
African HIV-infected children [21,22].
Immunologic status was significantly improved by
NNRTI-based HAART and sustained over a long period
(2, 3, 17). In our report, 89% of children had immune
recovery at 96 weeks which is higher than the 50%
Table 1 Baseline characteristics of children receiving
first-line NNRTI-based HAART
Characteristics* N
Age, years 107 6.2(4.2-8.9)
Female,% 107 52.3
CDC clinical classification N:A:B:C,% 107 4:44:30:22
Weight for age z-score 107 -1.5(-2.4 to -0.4)
Height for age z-score 107 -1.7(-2.6 to -1.1)
Weight for height z-score 107 -0.5(-1.6 to 0.3)
Hemoglobin, g/dL 78 10.6(9.5-11.7)
CD4% 101 7(3-15)
CD4 count, cells/mm3 101 151(35-477)
HIV-RNA log10 copies/ml 100 5(4.9-5.5)
NVP:EFV-based HAART,% 107 70:30
CDC: Center for Disease Control and Prevention, NVP: nevirapine, EFV:
efavirenz,
HAART: highly active antiretroviral therapy
*Data was shown in median (IQR) or percentage
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reported in a study of children from the northern part
of Thailand [3]. The children in our study were younger
and had higher baseline CD4, which could account for
the difference in outcome. The majority of HIV-infected
children have undetectable HIV-RNA after NNRTI-
based HAART initiation. The proportion of children
with undetectable HIV-RNA in our report was compar-
able to previous publications as of 70-75% [23,24].
In our study, 33% of children experienced VF. Varying
VF rates have been reported in other studies. Jittamala P.
et al. reported VF in 20% of 202 Thai HIV-infected chil-
dren, median duration of treatment until VF was 26
(range: 24-168) weeks [5]. Barth R. et al. reported VF in
38% of 81 HIV-infected children in rural South Africa
with the median duration of NNRTI-based HAART of 31
weeks [19]. The number of children in these studies with









Weight for age z-score -1.5(-2.4, -0.4) -1.1(-1.8,-0.6) -1.2(-2.0,-0.5) 0.014
Height for age z-score -1.7(-2.6, -1.1) -1.7(-2.3,-1.0) -1.4(-2.0,-0.6) <0.001
Weight for height z-score -0.5(-1.6, 0.3) -0.1(-0.6,0.5) -0.3(-1.2,0) >0.05
Laboratory outcomes
Hemoglobin (g/dL) 10.6(9.5-11.7) 12.1(11.0-12.7) 12.1(11-12.7) <0.001
CD4% 7(3-15) 21(15-25) 25(18-30) <0.001
CD4 count (cells/mm3) 151(35-477) 531(367-811) 707(422-915) <0.001
Percent of children with immune recovery (%) 0 82.2 89.1
Percent of children with HIV-RNA<1.7log10copies/ml (%) 0 69.1 75.0
ALT (U/L) 27(16-46) 22(16-28.5) 22(17-28) 0.01
Immune recovery was defined as recovery of CD4 to ≥ 25% after HAART initiation
*Data was shown in median (IQR)
Numbers of failure are shown in parentheses.   
 
Virologic failure was defined as HIV-RNA>1,000 copies/ml 
Figure 1 Kaplan-Meier proportion of virologic failure.
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VF indicated a need of second-line antiretroviral therapy;
VF mostly occurred in the first year of HAART [5,19].
Early detection of VF might allow for more second-line
options. Therefore, HIV-RNA performed at 6 and 12
months after NNRTI-based HAART initiation could
potentially capture the most failing children.
The sensitivity of IF in our study was low and is com-
parable to previous results in African HIV-infected chil-
dren of 3.5% of clinical and immunologic criteria in
identifying VF [13]. The criterion of IF is less sensitive to
detect treatment failure compared to VF and should not
be recommended [19]. However, IF criteria may continue
to be used in resource-limited settings because HIV-RNA
measurements are not as available as CD4 measurements.
Predictors associated with VF have been reported. Low
CD4% at baseline (< 25%), and physician documentation
of poor adherence were associated with VF (P < 0.05) in
one study [13]. Another study reported Thai HIV-
infected children receiving NVP to be 3.7 times more
likely to develop VF than those receiving EFV (P = 0.006)
[5]. However, we found no association of low CD4% or
NNRTI type and VF in our report. This may be explained
by limited number of children in our study.
Adverse events after NNRTI-based HAART com-
mencement were reported. Using zidovudine has been
related to severe anemia [25]. The proportion of children
with elevated ALT grades 3-4 in our study was 1% which
is lower than 3.4% in African HIV-infected children in a
previous report [26]. Dyslipidemia is a common observa-
tion among HIV-infected children after HAART[27]
which need the long-term follow-up.
This strength of study is the efficacy data of HIV-
infected children in resource-limited setting with HIV-
RNA measurement. This study has some limitation as
genotypic resistance testing was not available at the time
the study was conducted. There is inadequate data on
the best strategy for HIV-RNA monitoring [10], there-
fore the future studies should be conducted to evaluate
the best approaches to use HIV-RNA monitoring.
Conclusion
In summary, NNRTI-based HAART has shown signifi-
cant improvement of clinical, immunologic and virologic
outcomes. At 96 weeks, 75% of children had suppressed
plasma HIV-RNA and 89% had immune recovery.
Almost all of VF occurred in the first year after HAART
initiation. Immunologic failure had low sensitivity and
should not be relied on as a monitoring for treatment
failure. Plasma HIV-RNA should be performed once, and
preferably twice, in the first year after NNRTI-based
HAART to detect early treatment failure, and subse-
quently once a year if feasible as a routine monitoring for
all on HAART.
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